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11β-hydroxysteroid dehydrogenase 
type 1 has no effect on survival 
during experimental malaria but 
affects parasitemia in a parasite 
strain-specific manner
L. Vandermosten1, C. De Geest1, S. Knoops1, G. Thijs1, K. E. Chapman2, K. De Bosscher3,  
G. Opdenakker1 & P. E. Van den Steen1
Malaria is a global disease associated with considerable mortality and morbidity. An appropriately 
balanced immune response is crucial in determining the outcome of malarial infection. The 
glucocorticoid (GC) metabolising enzyme, 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) 
converts intrinsically inert GCs into active GCs. 11β-HSD1 shapes endogenous GC action and is 
immunomodulatory. We investigated the role of 11β-HSD1 in two mouse models of malaria. 11β-
HSD1 deficiency did not affect survival after malaria infection, but it increased disease severity and 
parasitemia in mice infected with Plasmodium chabaudi AS. In contrast, 11β-HSD1 deficiency rather 
decreased parasitemia in mice infected with the reticulocyte-restricted parasite Plasmodium berghei 
NK65 1556Cl1. Malaria-induced antibody production and pathology were unaltered by 11β-HSD1 
deficiency though plasma levels of IL-4, IL-6 and TNF-α were slightly affected by 11β-HSD1 deficiency, 
dependent on the infecting parasite. These data suggest that 11β-HSD1 is not crucial for survival of 
experimental malaria, but alters its progression in a parasite strain-specific manner.
Malaria is a global health problem with an estimated 200 million clinical cases and 438,000 deaths in 20151. 
Usually, malaria manifests as a mild febrile disease but complications can arise and include cerebral malaria (CM), 
severe malarial anaemia, placental malaria, hypoglycaemia and malaria-associated acute respiratory distress syn-
drome (MA-ARDS). Current antimalarial drugs effectively inhibit parasite growth but cannot resolve malaria 
complications, resulting in a mortality of about 15% for CM and up to 80% for MA-ARDS2–4. The immune 
response to malaria needs to be well balanced in order to control the infection without causing an overwhelm-
ing inflammation5–7. Inflammatory processes are thought to contribute significantly to the pathogenesis of spe-
cific malaria complications. For example, MA-ARDS is characterized by alveolar inflammation with infiltrating 
monocytes, macrophages, lymphocytes and neutrophils3. Anti-inflammatory molecules are essential to prevent 
immunopathology and include interleukin-10 (IL-10), transforming growth factor-β (TGF-β), heme oxygenase 1 
(HO-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)8–13. In previous studies, an increase in blood 
cortisol levels was reported in P. falciparum- or P. vivax-infected patients, compared to healthy controls14–22. 
Cortisol levels decline during treatment as the clinical symptoms and parasitemia decrease23. One study reported 
that cortisol levels are higher in P. falciparum-infected patients with CM compared to uncomplicated malaria14. 
As glucocorticoids (GCs) have broad and potent immune-modulatory effects, they might be important in malaria 
to protect against excessive inflammation and its related complications. However, in two clinical trials conducted 
about 30 years ago, dexamethasone was tested in patients with CM without any benefit24,25. Nevertheless, and 
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despite the established findings of increased endogenous GC levels in patients, surprisingly little is known about 
their importance and precise role during malaria infection.
Within cells, GC levels are regulated by 11β-hydroxysteroid dehydrogenase-1 and -2 (11β-HSD1 and 2) 
enzymes, which activate and inactivate endogenous GCs, respectively26. 11β-HSD1 amplifies intracellular GC 
levels (intracrine effects) and in addition contributes to ~30–40% of total active cortisol production in humans 
(endocrine effect) via the splanchnic bed which consists of the liver (highly expressing 11β-HSD1), gut and mes-
entery26. Knock-out of 11β-HSD1 abolishes GC regeneration while basal plasma corticosterone levels are main-
tained due to enhanced adrenal production27.
11β-HSD1 is widely expressed in immune cells and is regulated in a cell-specific manner, dependent on 
the cell activation state. During inflammation, when the hypothalamic-pituitary-adrenal (HPA) axis is acti-
vated, 11β-HSD1 is especially upregulated in activated immune cells, further amplifying endogenous GCs26,28. 
11β-HSD1 expression is enhanced in dendritic cells (DCs) upon differentiation and innate immune induced mat-
uration. This enhances the GC bioavailability and thus negatively regulates full DC differentiation, maturation, 
plasmacytoid DC survival and DC function29,30. 11β-HSD1 is important in restraining acute inflammation. The 
number of recruited inflammatory cells is increased in 11β-HSD1-deficient mouse models of inflammation in 
which neutrophils predominate in the inflammatory response31. Moreover, the switch from a pro-inflammatory, 
injury or tissue damaging (M1) response to a pro-resolution repair phase (M2) occurs earlier in 11β-HSD1 knock 
out mice28. Following LPS stimulation in vitro, macrophages are polarized to an M1 phenotype with high expres-
sion of 11β-HSD128. 11β-HSD1-deficient mice are more susceptible to sublethal dose LPS endotoxemia as shown 
by an elevated weight loss and increased circulatory levels of pro-inflammatory tumor necrosis factor-α (TNF-α), 
IL-6, and IL-12p40. This was attributed to a macrophage hypersensitive state with increased signalling of nuclear 
factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK)32. It was suggested that 11β-HSD1 alters the 
phenotypic differentiation rather than the glucocorticoid responsiveness of myeloid cells. In other models of 
acute inflammation, 11β-HSD1 deficiency caused an earlier onset of inflammation (K/BxN serum transfer model 
of inflammatory arthritis) or recruitment of more neutrophils and monocytes/macrophages (myocarditis), con-
sistent with a role for 11β-HSD1 in restraining acute inflammation33,34. The effect of 11β-HSD1 is not always 
beneficial as its deficiency or inhibition is associated with better recovery of heart function after coronary artery 
ligation, probably because in the infarct zone, macrophages accumulate and polarise earlier to an M2 pheno-
type34. Furthermore, peripheral tissue regeneration of GCs by 11β-HSD1, rather than circulating corticosterone 
levels, mediates the Cushingoid effects of circulating GC excess35.
The objective of the current study was to investigate the role of peripheral reactivation of endogenous GCs by 
11β-HSD1 in murine malarial disease. Therefore, we infected 11β-HSD1-deficient C57Bl/6 mice with two strains 
of murine Plasmodium parasites: P. chabaudi AS (PcAS) and Plasmodium berghei NK65 (PbNK65) 1556Cl1. 
Both these murine models are free of early lethality and thus serve well to observe even modest differences in 
disease course. PcAS-infected C57Bl/6 mice are able to clear the parasite and survive the infection despite a 
transient phase of liver inflammation36. This model is frequently used to study immune mechanisms since a 
parasite-controlling immune response develops. Important differences exist between the red blood cell (RBC) 
subset preference of malaria parasites. Some parasites are able to infect normocytes (e.g. P. falciparum and PcAS), 
while other parasites such as P. vivax, are restricted to reticulocytes37. To address this specificity, we also used the 
reticulocyte-restricted 1556Cl1 clone of PbNK65 which can cause late-stage hyperparasitemia.
Materials and Methods
Mice. In all experiments, 8–10 week old male and female mice were used and each experimental and con-
trol group contained similar numbers of each sex. All animal experiments were approved by the Animal Ethics 
Committee from the KU Leuven (License LA1210186, Belgium) and conformed to the European Directive 
2010/63/EU and the UK Animals (Scientific Procedures) Act 1986, as amended in 2012.
Mice homozygous for a null mutation in the gene encoding 11β-HSD1 (Hsd11b1Del/Del) on a C57Bl/6 genetic 
background have been described38 and were generated by crossing mice homozygous for an allele of Hsd11b1 
in which exon 3 is flanked by LoxP sites39 with mice expressing Cre recombinase under the control of the Hprt 
promoter, expressed in the germ line40. To generate non-transgenic littermates as wild-type (WT) controls, 
C57Bl/6 mice were mated with Hsd11b1Del/Del mice to yield F1 heterozygotes. The latter were inter-crossed to 
obtain Hsd11b1Del/Del mice and matched WT controls in the F2 generation. Overall, Hsd11b1Del/Del mice were 
backcrossed to C57Bl/6 mice for more than 6 generations. Strain background strongly influences the course of 
malarial infection in mice. To characterize the percentage of C57Bl/6 background of WT and Hsd11b1Del/Del mice, 
background strain characterization was performed on genomic tail DNA from 3 Hsd11b1Del/Del mice and 3 of their 
WT littermates (Taconic, Rensselaer, NY, USA). A panel of 1449 SNP markers, covering all chromosomes, was 
compared to a C57Bl/6 J reference strain. This confirmed that Hsd11b1Del/Del mice showed 99.93–100% similarity 
to the C57Bl/6 reference genome. The characterization of all SNPs can be found as Supplementary Table S1.
Infection of mice and clinical scoring. As described previously41, mice were housed in a conventional 
animal house and intraperitoneally injected with 104 RBCs infected with PcAS or PbNK65 clone 1556Cl1 (a 
kind gift of Prof. C.J. Janse, Leiden University Medical Center, The Netherlands; corresponding to PbNK65 NY 
strain42). Mice received high energy food ad libitum and drinking water was supplemented with para-amino ben-
zoic acid (PABA; Sigma-Aldrich, Bornem, Belgium) to facilitate in vivo parasite growth.
Body weight, parasitemia, and clinical parameters including spontaneous activity (SA), limb grasping (LG), 
body tone (BT), trunk curl (TC), pilo-erection (PE), shivering (Sh), abnormal breathing (AB), dehydration (D), 
incontinence (I) and paralysis (P) were evaluated daily to calculate a clinical score of disease severity. A disease 
score was given of 0 (absent) or 1 (present) for TC, PE, Sh and AB and 0 (normal), 1 (intermediate) or 2 (most 
serious) for the other parameters. The total clinical score was calculated by the following formula: SA + LG + BT 
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+ TC + PE + Sh + AB + 3*(D + I + P). Peripheral parasitemia (percentage of RBCs that are infected) was deter-
mined by microscopic analysis of blood smears after Giemsa staining (VWR, Leuven, Belgium). Mice were euth-
anized when the humane endpoints were reached (clinical score of 15 or more) or at the indicated time points.
Collection of tissues. Upon euthanasia, blood was collected by heart puncture. The left lung was pinched off 
and bronchoalveolar lavage fluid (BALF) was collected from the right lung as described previously41. Mice were 
systemically perfused (transcardial route) with PBS to remove circulating blood. Organs were removed, weighed 
and stored at −80 °C.
Determination of glucose, protein and cytokine levels and assessment of liver pathol-
ogy. Blood samples were centrifuged and plasma glucose concentrations were measured in duplicate or 
triplicate using a OneTouch Verio meter (LifeScan, Zurich, Switzerland). Plasma levels of interferon-γ (IFN-γ), 
TNF-α, IL-4, IL-5 and IL-6 were determined with a ProcartaPlex multiplex immunassay panel (EPX060-20831-
901, Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer’s protocol. Liver func-
tion was assessed by measurement of plasma alanine aminotransferase (ALT) and aspartate transaminase (AST) 
using a reagent set according to the manufacturer’s protocols (Teco Diagnostics, California, USA). BALF samples 
were centrifuged and protein concentrations of the supernatants were determined by Bradford assay (Bio-Rad, 
Hercules, CA, USA).
Preparation of crude parasite antigen. A crude parasite antigen was prepared from blood from 10 
PcAS-infected mice with a method modified from Elliot et al.43. The serum was removed from the blood by 
centrifugation (15 min. at 524 g) and the remaining pellet was washed three times with PBS (centrifugation for 
10 min. at 3,000 g). The pellet was resuspended in PBS and cells were lysed with saponin (0.01%) for 20 min at 
37 °C. The pellet from the lysate was washed with PBS (centrifugation for 20 min. at 20,000 g) until the superna-
tant was clear and colourless, resuspended in water and sonicated. The protein concentration was determined by 
Bradford analysis.
Measurement of malaria-specific antibody levels in plasma. Circulating plasma levels of 
anti-parasitic IgG and IgM were determined by a direct ELISA with a method modified from Li et al.44 as reported 
previously45. 96 well NUNC immunoplates were coated overnight at 4 °C with the crude parasite antigen (5 µg/ml 
in 0.1 M NaHCO3, pH 9.6). After washing and blocking (in 1% BSA and 0.1% Tween 20 in PBS), serial dilutions 
of plasma samples and a laboratory standard were added to the wells and the plate was incubated for 1 h at 37 °C. 
The laboratory standard was prepared by pooling plasma samples from several mice, 21 days post-infection, and 
was given an arbitrary concentration of 90,000 laboratory standard units (LSU) per ml. For detection, 1/5,000 
HRP-conjugated anti-mouse IgG or IgM (respectively, Fcγ or µ-chain specific, Jackson-Immunoresearch, West 
Grove, PA, USA) was added. The plate was incubated for 1 h at 37 °C, washed and HRP activity was visualized by 
adding TMB (0.55 µM, Sigma-Aldrich) and H2O2 (0.004% Merck, Darmstadt, Germany), in citrated acetate buffer 
(0.1 M) pH 4.3. The reaction was stopped with H2SO4 (1 M) and optical densities were determined at 450 nm on 
a microplate spectrophotometer (Power Wave XS, Biotek, Winooski, VT, USA).
Statistical analysis. GraphPad Prism Software (GraphPad Software, San Diego, CA) was used for all statis-
tical analyses. The non-parametric two-tailed Mann-Whitney U-test was used to calculate significance levels for 
the differences between groups. The non-parametric two-tailed Fisher exact test was used to compare proportions 
between two groups. GraphPad Prism software was also used to calculate the significance levels for the survival 
curves with the Log-rank (Mantel-Cox) Test. *p < 0.05, **p < 0.01, ***p < 0.001.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files.
Results
11β-HSD1 deficiency does not affect survival upon PcAS infection but changes parasitemia and 
disease severity. To determine whether peripheral reactivation of endogenous GCs has an effect on malarial 
disease, Hsd11b1Del/Del and WT mice were infected with the malarial parasite PcAS. All PcAS-infected Hsd11b1Del/Del  
and WT mice survived to the end of the experiment (Fig. 1a). The parasitemia showed a modest but significant 
(p = 0.04) increase at day 11 post-infection in Hsd11b1Del/Del mice compared to WT littermates (Fig. 1b). Also, the 
peak clinical score occurred one day earlier and was greater (p = 0.01) in Hsd11b1Del/Del mice compared to WT 
(Fig. 1c). Spontaneous activity, body tone and limb grasping determined the increase in clinical score, while the 
other, more severe used scoring parameters were rarely observed. No difference in body weight loss was observed 
between both genotypes (Fig. 1d).
Thus, 11β-HSD1 deficiency does not affect the survival upon infection with PcAS, despite increased para-
sitemia and clinical score.
11β-HSD1 influences IL-4 levels but is not essential for the production of antimalarial anti-
bodies or the prevention of malaria-associated pathology. To evaluate the elicited cytokine 
response, plasma levels of several cytokines were determined at peak parasitemia, 10 days post-infection (Fig. 2). 
Circulatory IFN-γ, IL-4, IL-5, IL-6 and TNF-α were increased in WT mice after infection with PcAS (respec-
tively, p = 0.004, 0.004, 0.0081, 0.004 and 0.004). In Hsd11b1Del/Del mice, only IL-4 and TNF-α were significantly 
increased in response to the infection (respectively, p = 0.0061, 0.0061), and non-significant trends were noted 
for IFN-γ, IL-5 and IL-6 (respectively, p = 0.103, 0.109, 0.103). Notably, levels of IL-4 were increased to a greater 
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extent in Hsd11b1Del/Del mice than in WT (p = 0.037) while IFN-γ, IL-5, IL-6 and TNF-α plasma concentrations 
did not differ between genotypes (p = 0.96, 0.40, 0.54, 0.28, respectively).
Three weeks after infection with PcAS, anti-parasitic IgG and IgM were increased in WT and Hsd11b1Del/Del 
mice (respectively p = 0.0002 and p = 0.0011 Fig. 3a; p = 0.0002 and p = 0.0011 Fig. 3b). However, there were no 
differences in antibody levels between PcAS-infected Hsd11b1Del/Del and WT mice (p = 0.82 Fig. 3a and p = 0.97 
Fig. 3b). This indicates that 11β-HSD1-deficiency has no effect on the humoral immune response against PcAS 
parasites.
Plasma glucose levels were measured, since GCs and 11β-HSD1 have metabolic effects besides their 
immune-modulatory properties and malaria-infection is known to affect glycaemia26,46,47. However, at peak 
parasitemia, 10 days post-infection, a similar (p = 0.088) decrease in plasma glucose levels was observed in 
PcAS-infected Hsd11b1Del/Del and WT mice (p = 0.0014 and <0.0001, respectively), compared to uninfected mice 
(Fig. 4a).
Liver damage and lung inflammation may occur following malarial infection36,41. As an indicator of liver dam-
age, plasma levels of ALT and AST were measured (Fig. 4b,c). At peak parasitemia, ALT levels were significantly 
increased in Hsd11b1Del/Del mice compared to uninfected controls (p = 0.035) and a similar trend was observed 
in WT mice (p = 0.11). AST levels were elevated in both Hsd11b1Del/Del (p < 0.0001) and WT mice (p = 0.0004) 
upon infection. However, neither ALT nor AST were significantly different between infected Hsd11b1Del/Del and 
WT mice (p = 0.98 and p = 0.57, respectively).
Lung inflammation was evaluated by measuring the lung weight and by determining the protein content in 
the BALF at peak parasitemia (Fig. 4d,e). Compared to uninfected controls, Hsd11b1Del/Del mice showed a modest 
but significant increase in lung weight (p = 0.015), while infected WT mice only showed a trend towards heavier 
lungs (p = 0.093). However, a more accurate assessment of lung pathology by protein content in the BALF did 
not indicate a significant alteration upon infection with PcAS (p = 0.13 for WT and p = 0.88 for Hsd11b1Del/Del). 
Moreover, these indicators of lung pathology did not differ between Hsd11b1Del/Del and WT mice (p = 0.80 for 
lung weight and p = 0.80 for BALF).
Figure 1. 11β-HSD1 deficiency does not affect survival, but it increases parasitemia and clinical disease score in 
PcAS-infected mice. Hsd11b1Del/Del and WT mice were infected with Plasmodium chabaudi AS (PcAS). (a) The 
survival was monitored daily. The peripheral parasitemia (b), clinical score (c) and body weight (d) of the mice was 
determined at the indicated time points. Survival was analysed by Log-rank test. Data are means ± SEM and were 
analysed by Mann-Whitney U-test. Asterisks on top indicate a difference between the infected Hsd11b1Del/Del and 
WT mice. Data from 2 separate experiments. n = 10 (6 females (F) and 4 males (M)) for WT and n = 12 (6 F and 
6 M) for Hsd11b1Del/Del.
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Overall, these data show that 11β-HSD1 deficiency increases IL-4 levels in response to PcAS infection, but 
does not influence malaria-associated antibody production or pathology.
Effect of 11β-HSD1 deficiency on infection with the reticulocyte-restricted PbNK65 
1556Cl1. PcAS infects normocytes as well as reticulocytes. To investigate whether 11β-HSD1 deficiency also 
alters parasitemia and clinical score with a reticulocyte-restricted malarial strain, Hsd11b1Del/Del mice and their 
WT littermates were infected with PbNK65 1556Cl1.
A proportion of the infected mice developed lethal hyperparsitemia, whereas in the other mice, parasitemia 
remained below 6% during the observed course of the experiment. There was a trend towards a higher survival 
in PbNK65 1556Cl1-infected Hsd11b1Del/Del compared to WT mice (Log-rank test p = 0.14; Fig. 5a), in line with 
a trend for fewer Hsd11b1Del/Del mice developing lethal hyperparasitemia compared to WT mice (27.78% ver-
sus 56.25%; Fisher exact test p = 0.16) (Fig. 5c,d). The trend towards a reduction in lethal hyperparasitemia in 
Hsd11b1Del/Del mice compared to WT was paralleled by a lower group mean clinical score in the third week of 
infection (Fig. 5e; p = 0.020, 0.037, 0.047 for respectively d17, 19, 20) without an effect on body weight (Fig. 5g). 
Hyperparasitemic (HP) Hsd11b1Del/Del and WT mice died at a similar time point, 21 to 24 days after infection 
(Fig. 5b). When the analysis was restricted to HP or non-HP mice only, no difference in the clinical score was 
found between genotypes (Fig. 5f and Supplementary Fig. S1). Clinical symptoms were either absent or very mild 
in non-HP mice. Interestingly, of the mice that developed hyperparasitemia, Hsd11b1Del/Del mice showed a greater 
body weight loss compared to WT within the first two weeks of infection, when parasitemia levels were still low 
(Fig. 5h; p = 0.013, 0.017, 0.042, 0.020 respectively, for d7–9 and d13). This difference in body weight loss was not 
observed in the non-HP mice (Supplementary Fig. S1).
There was no significant difference in reticulocytosis between Hsd11b1Del/Del and WT mice at 17 days after 
infection (p = 0.20; Fig. 6). Also, the abundant reticulocytosis (16% in infected versus ≤3% in non-infected mice) 
Figure 2. The effect of 11β-HSD1 on plasma levels of IFN-γ, IL-4, IL-5, IL-6 and TNF-α upon infection with 
PcAS. Hsd11b1Del/Del and WT mice were infected with PcAS. At the peak of infection, 10 days post-infection, 
plasma levels of IFN-γ, IL-4, IL-5, IL-6 and TNF-α were measured. The dotted line indicates the limit of 
detection and samples with a measurement below the detection limit, were given an arbitrary value of half of 
the detection limit. Each dot represents the result from an individual mouse. Horizontal lines in between data 
points represent group medians and analysis was by Mann-Whitney U-test. Asterisks above individual data sets 
indicate statistical differences compared to the uninfected control group. n = 8 (4 F and 4 M) for WT and n = 7 
(4 F and 3 M) for Hsd11b1Del/Del. ns, not significant.
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occurred both in HP and non-HP mice (Fig. 6). Only in non-HP mice, a lower reticulocytosis was noted in WT 
mice compared to Hsd11b1Del/Del mice (p = 0.017; Supplementary Fig. S2).
The levels of IFN-γ, IL-4, IL-5, IL-6 and TNF-α were measured in the plasma of HP and non-HP PbNK65 
1556Cl1-infected Hsd11b1Del/Del and WT mice at 21 to 24 days (HP) or 28 days (non-HP) after infection 
(Supplementary Fig. S3). Compared to uninfected controls, cytokine levels of non-HP mice remained at base-
line, while in HP mice, the levels were increased upon infection. In the HP mice, a higher increase of IL-6 levels 
(p = 0.030) and a trend towards a higher increase of TNF-α levels (p = 0.052) were observed in Hsd11b1Del/Del 
versus WT mice.
Taken together, we have shown that 11β-HSD1 deficiency resulted in a trend towards less lethal hyperpara-
sitemia with the reticulocyte-restricted parasite strain PbNK65 1556Cl1. This was paralleled by increased plasma 
levels of IL-6.
Discussion
To determine whether peripheral reactivation of endogenous GCs has an effect on malarial disease, we studied 
the phenotype of Hsd11b1Del/Del mice. 11β-HSD1 deficiency altered parasitemia and clinical disease score in mice 
infected with PcAS or PbNK65 1556Cl1. PcAS-infected Hsd11b1Del/Del mice showed increased parasitemia and 
clinical score, whereas a trend was observed for fewer PbNK65 1556Cl1-infected Hsd11b1Del/Del mice to develop 
lethal hyperparasitemia. Thus, 11β-HSD1 clearly influences parasitemia in a parasite strain-dependent manner.
PcAS has been frequently used to study immune mechanisms, as resistant mouse strains such as C57Bl/6 mice 
develop an immune response that controls the parasite. To control the initial replication of the parasite, innate 
immune rather than antibody-mediated mechanisms are essential48. Both DCs and macrophages are central in 
the innate immune response to the parasite. DCs endocytose the parasite, produce IL-12 and present antigens to 
CD4+ T cells48. Macrophages are able to phagocytose infected RBCs via CD36 and they sense parasite-associated 
components which trigger cytokine production49,50. 11β-HSD1 affects macrophages and DCs. The enzyme inhib-
its full DC differentiation, maturation, plasmacytoid DC survival and DC function29,30. Expression of 11β-HSD1 
is induced upon differentiation of monocytes into macrophages and even more in M1 polarised macrophages28. 
McSweeney et al. showed that 11β-HSD1 deficient mice switch earlier to an M2 phenotype after myocardial 
infarction34. Here, we observed mildly increased levels of IL-4 in Hsd11b1Del/Del mice compared to WT mice 
upon PcAS infection. IL-4 can stimulate M2 macrophage activation which may mirror a Th2 polarization51. Th1/
M1 rather than Th2/M2 type reactions are crucial for an efficient anti-malarial immunity, especially in the early 
stage6. IL-4 slightly delays parasite clearance in P. yoelii 17XNL-infected mice, although it can also suppress recru-
descences upon PcAS infection52,53. The increase in IL-4 production in 11β-HSD1 deficient mice might thus 
indicate a greater or earlier polarisation to M2 macrophages, resulting in a less efficient parasite clearance and the 
observed increase in parasitemia. The generation of cell-specific 11β-HSD1 knockout mice may provide useful 
tools to identify the importance of 11β-HSD1 in macrophages or DCs during malaria infection. After the initial 
phase of innate immunity, the adaptive immunity plays an important role in clearing the infection6. Anti-parasitic 
antibody levels did not differ between WT and Hsd11b1Del/Del mice. Therefore, the effect of 11β-HSD1 on PcAS 
parasitemia was not attributed to a change in parasite-specific antibody production.
The parasitemia course and the effect of 11β-HSD1 on the parasitemia differs between PbNK65 1556Cl1 and 
PcAS-infected mice. A difference in infected RBC type, in provoked immune response or both might be the cause 
Figure 3. 11β-HSD1 has no effect on the production of malaria-specific IgG and IgM. Hsd11b1Del/Del and WT 
mice were infected with PcAS. Malaria-specific antibody levels in plasma were analysed by ELISA at 21 days 
post-infection. Each dot represents the result from an individual mouse. Horizontal lines in between data 
points represent group medians and analysis was by Mann-Whitney U-test. Asterisks above individual data sets 
indicate statistical differences compared to the uninfected control group. Data from 2 separate experiments. 
n = 10 (6 F and 4 M) for WT and n = 12 (6 F and 6 M) for Hsd11b1Del/Del. ns, not significant.
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of the opposite effects in the two models. Regarding the infected RBC type, we showed in preliminary experi-
ments that PbNK65 1556Cl1 parasites are restricted to reticulocytes and do not infect normocytes, in accordance 
to the findings by Deharo et al.54. These infections thus depend on erythropoiesis, as parasitemia is limited by 
the number of available reticulocytes. Hyperparasitemia can therefore only occur when high reticulocytosis is 
induced due to anemia. GCs may increase erythropoiesis during malaria infection by stimulating self-renewal 
of an early erythroid progenitor55. However, deficiency in 11β-HSD1 did not impede the erythropoiesis upon 
infection, since similar numbers of reticulocytes were found in both genotypes. Here, a proportion of PbNK65 
1556Cl1-infected mice developed hyperparasitemia at a late stage of infection, together with a considerable retic-
ulocytosis. The reasons why some mice do not develop hyperparasitemia are not related to reticulocytosis, and 
could therefore be the consequence of the immune response. The role of both innate and adaptive immunity 
on parasite control is complex and has been widely investigated6. In HP PbNK65 1556Cl1-infected mice, IL-6 
was significantly increased in the absence of 11β-HSD1, and a trend towards increased TNF-α was noted. This 
effect might reflect a decrease in anti-inflammatory GC activity. Previous work has established that in LPS endo-
toxemia, 11β-HSD1 deficiency is associated with higher levels of TNF-α and IL-632. However, in contrast to 
PcAS-infected mice, no difference in IL-4 response was seen in PbNK65 1556Cl1-infected mice. This indicates 
that the effect of 11β HSD1 on the cytokine response depends on the parasite strain.
Despite the shift in parasitemia, 11β-HSD1 did not affect survival in the studied murine malaria models. Also, 
the malaria-associated pathology was not altered after infection with PcAS. This is in contrast to LPS-induced 
inflammation which is aggravated in the absence of 11β-HSD132. Furthermore, GCs themselves are essential to 
survive LPS-mediated endotoxemia or other infections, for example with murine cytomegalovirus or with bacte-
ria that produce toxins such as C. difficile toxin A, Shiga toxin 2 or superantigen SEB56–58. Also, infections can trig-
ger an Addisonian crisis in patients with adrenal insufficiency59. In this context, it should be noted that although 
11β-HSD1 is essential for intracellular regeneration of GCs, 11β-HSD1 deficiency or inhibition is associated with 
increased adrenal production of GCs to maintain normal circulating levels27,28. Thus, we have shown that intra-
cellular regeneration of GCs can modulate cytokine responses and the course of disease during malaria infection.
Figure 4. 11β-HSD1 does not change plasma glucose, ALT or AST levels and does not affect lung pathology 
upon infection with PcAS. Hsd11b1Del/Del and WT mice were infected with PcAS. At the peak of infection, 
10 days post-infection, plasma glucose levels, alanine aminotransferase (ALT) and aspartate transaminase 
(AST) levels were measured. Also, the weight of the left lung and the protein content in the bronchoalveolar 
lavage fluid (BALF) were determined. Each dot represents the result from an individual mouse. Horizontal 
lines in between data points represent group medians and analysis was by Mann-Whitney U-test. Asterisks 
above individual data sets indicate statistical differences compared to the uninfected control group. Data 
from 2 separate experiments. n = 16 (8 F and 8 M) for WT and n = 15 (8 F and 7 M) for Hsd11b1Del/Del. ns, not 
significant.
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Figure 5. Effect of 11β-HSD1 on the disease and parasitemia course in PbNK65 1556Cl1-infected mice. 
Hsd11b1Del/Del and WT mice were infected with Plasmodium berghei NK65 (PbNK65) clone 1556Cl1 and a 
differentiation was made between hyperparasitemic (HP) and non-hyperparasitemic (non-HP) mice. For the 
clinical score and body weight of non-HP mice, see supplementary Fig. S1. Survival (a,b), individual peripheral 
parasitemia (c,d), clinical score (e,f) and body weight (g,h) of the mice is shown. Survival was analysed by 
Log-rank test. Data are means ± SEM and were analysed by Mann-Whitney U-test. Asterisks on top indicate a 
difference between the infected Hsd11b1Del/Del and WT mice. Data from 2 separate experiments. n = 16 (7 F and 
9 M) for WT and n = 18 (9 F and 9 M) for Hsd11b1Del/Del. n = 9 (3 F and 6 M) for HP WT and n = 5 (2 F and 3 M) 
for HP Hsd11b1Del/Del.
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Blood glucose levels were decreased upon malaria infection to a similar extent in WT and Hsd11b1Del/Del mice, 
consistent with findings that 11β-HSD1 deficiency does not induce fasting hypoglycemia60. This indicates that 
glucose counter-regulatory responses are not affected by 11β-HSD1 deficiency despite the reduced induction of 
glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activity upon starvation26,60. In contrast, in the 
case of hyperglycemia in obese or diabetic mice, 11β-HSD1 deficiency or inhibition of 11β-HSD1 results in lower 
fasting glucose levels, attributed to decreased hepatic gluconeogenesis and increased insulin sensitivity26.
Overall, this study indicates that 11β-HSD1 is not crucial for survival but alters parasitemia and cytokine 
response during malaria in a Plasmodium strain-specific manner. A major difference between the murine 
parasites, used here, is their RBC subset preference, with PbNK65 being restricted to reticulocytes and PcAS 
infecting normocytes. From this perspective, it may be hypothesized that 11β-HSD1 might also increase hyper-
parasitemia in patients with (reticulocyte restricted) P. vivax malaria, whereas it might limit parasitemia in P. 
falciparum-infected patients. In the future, it will be of interest to analyse HSD11B1 genotype differences (SNPs) 
in malaria patients.
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